Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Executive Summary
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
You May Also Like
Next Logical Step
Introducing MentalHealthBench
MentalHealthBench is an expert-informed benchmark for evaluating helpful and safe AI responses across realistic mental h...